NEW YORK, March 30, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against JBS S.A. (“JBS” or the “Company”) (OTC:JBSAY) and certain of its officers, on behalf of shareholders who purchased JBS American Depositary Receipts between June 2, 2015 and March 17, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/jbs.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and failed to disclose that: (1) JBS executives bribed regulators and politicians to subvert food inspections of its plants and overlook unsanitary practices such as processing rotten meat and running plants with traces of salmonella; and (2) consequently, defendants’ statements about JBS’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On March 17, 2017, several news sources reported that Brazilian federal police raided JBS offices and other meatpackers after a two-year investigation of regulators alleged bribery regarding the inspections of their facilities. The investigation, known as “Operation Weak Flesh,” exposed roughly 40 cases of meatpackers who bribed inspectors and politicians to overlook unsanitary procedures such as processing rotten meat and running plants with traces of salmonella. Brazilian police arrested two JBS employees, and 20 public officials. JBS said in a securities filing that three of its facilities and one of its employees were targeted in the probe. Following this news, JBS stock dropped $0.71 per share or over 9.2% to close at $6.96 per share on March 17, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/jbs or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in JBS you have until May 22, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
BlueScope Steel Announces A$1 Special Dividend After Asset Sales
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 



